Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1990 Apr;3(2):153–170. doi: 10.1128/cmr.3.2.153

Vaccinia virus vectors: new strategies for producing recombinant vaccines.

D E Hruby 1
PMCID: PMC358149  PMID: 2187593

Abstract

The development and continued refinement of techniques for the efficient insertion and expression of heterologous DNA sequences from within the genomic context of infectious vaccinia virus recombinants are among the most promising current approaches towards effective immunoprophylaxis against a variety of protozoan, viral, and bacterial human pathogens. Because of its medical relevance, this area is the subject of intense research interest and has evolved rapidly during the past several years. This review (i) provides an updated overview of the technology that exists for assembling recombinant vaccinia virus strains, (ii) discusses the advantages and disadvantages of these approaches, (iii) outlines the areas of outgoing research directed towards overcoming the limitations of current techniques, and (iv) provides some insight (i.e., speculation) about probable future refinements in the use of vaccinia virus as a vector.

Full text

PDF
153

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrew M. E., Boyle D. B., Coupar B. E., Whitfeld P. L., Both G. W., Bellamy A. R. Vaccinia virus recombinants expressing the SA11 rotavirus VP7 glycoprotein gene induce serotype-specific neutralizing antibodies. J Virol. 1987 Apr;61(4):1054–1060. doi: 10.1128/jvi.61.4.1054-1060.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andrew M. E., Coupar B. E., Ada G. L., Boyle D. B. Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microb Pathog. 1986 Oct;1(5):443–452. doi: 10.1016/0882-4010(86)90006-9. [DOI] [PubMed] [Google Scholar]
  3. Andrew M. E., Coupar B. E., Boyle D. B., Ada G. L. The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand J Immunol. 1987 Jan;25(1):21–28. doi: 10.1111/j.1365-3083.1987.tb01042.x. [DOI] [PubMed] [Google Scholar]
  4. Auperin D. D., Esposito J. J., Lange J. V., Bauer S. P., Knight J., Sasso D. R., McCormick J. B. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res. 1988 Feb;9(2-3):233–248. doi: 10.1016/0168-1702(88)90033-0. [DOI] [PubMed] [Google Scholar]
  5. Ball L. A., Young K. K., Anderson K., Collins P. L., Wertz G. W. Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc Natl Acad Sci U S A. 1986 Jan;83(2):246–250. doi: 10.1073/pnas.83.2.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baylor N. W., Li Y., Ye Z. P., Wagner R. R. Transient expression and sequence of the matrix (M1) gene of WSN influenza A virus in a vaccinia vector. Virology. 1988 Apr;163(2):618–621. doi: 10.1016/0042-6822(88)90303-0. [DOI] [PubMed] [Google Scholar]
  7. Bennink J. R., Yewdell J. W., Smith G. L., Moss B. Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J Virol. 1987 Apr;61(4):1098–1102. doi: 10.1128/jvi.61.4.1098-1102.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Berger E. A., Fuerst T. R., Moss B. A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2357–2361. doi: 10.1073/pnas.85.7.2357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bernards R., Destree A., McKenzie S., Gordon E., Weinberg R. A., Panicali D. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6854–6858. doi: 10.1073/pnas.84.19.6854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Boone R. F., Moss B. Sequence complexity and relative abundance of vaccinia virus mRNA's synthesized in vivo and in vitro. J Virol. 1978 Jun;26(3):554–569. doi: 10.1128/jvi.26.3.554-569.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bossart W., Nuss D. L., Paoletti E. Effect of UV irradiation on the expression of vaccinia virus gene products synthesized in a cell-free system coupling transcription and translation. J Virol. 1978 Jun;26(3):673–680. doi: 10.1128/jvi.26.3.673-680.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Boursnell M. E., Foulds I. J., Campbell J. I., Binns M. M. Non-essential genes in the vaccinia virus HindIII K fragment: a gene related to serine protease inhibitors and a gene related to the 37K vaccinia virus major envelope antigen. J Gen Virol. 1988 Dec;69(Pt 12):2995–3003. doi: 10.1099/0022-1317-69-12-2995. [DOI] [PubMed] [Google Scholar]
  13. Boyle D. B., Coupar B. E., Both G. W. Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene. 1985;35(1-2):169–177. doi: 10.1016/0378-1119(85)90169-6. [DOI] [PubMed] [Google Scholar]
  14. Brown F., Schild G. C., Ada G. L. Recombinant vaccinia viruses as vaccines. Nature. 1986 Feb 13;319(6054):549–550. doi: 10.1038/319549a0. [DOI] [PubMed] [Google Scholar]
  15. Browne H. M., Churcher M. J., Stanley M. A., Smith G. L., Minson A. C. Analysis of the L1 gene product of human papillomavirus type 16 by expression in a vaccinia virus recombinant. J Gen Virol. 1988 Jun;69(Pt 6):1263–1273. doi: 10.1099/0022-1317-69-6-1263. [DOI] [PubMed] [Google Scholar]
  16. Buller R. M., Chakrabarti S., Cooper J. A., Twardzik D. R., Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol. 1988 Mar;62(3):866–874. doi: 10.1128/jvi.62.3.866-874.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Buller R. M., Smith G. L., Cremer K., Notkins A. L., Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. 1985 Oct 31-Nov 6Nature. 317(6040):813–815. doi: 10.1038/317813a0. [DOI] [PubMed] [Google Scholar]
  18. Cantin E. M., Eberle R., Baldick J. L., Moss B., Willey D. E., Notkins A. L., Openshaw H. Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5908–5912. doi: 10.1073/pnas.84.16.5908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol. 1985 Dec;5(12):3403–3409. doi: 10.1128/mcb.5.12.3403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Chakrabarti S., Robert-Guroff M., Wong-Staal F., Gallo R. C., Moss B. Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature. 1986 Apr 10;320(6062):535–537. doi: 10.1038/320535a0. [DOI] [PubMed] [Google Scholar]
  21. Chambers T. M., Kawaoka Y., Webster R. G. Protection of chickens from lethal influenza infection by vaccinia-expressed hemagglutinin. Virology. 1988 Dec;167(2):414–421. [PubMed] [Google Scholar]
  22. Chaudhary V. K., Mizukami T., Fuerst T. R., FitzGerald D. J., Moss B., Pastan I., Berger E. A. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature. 1988 Sep 22;335(6188):369–372. doi: 10.1038/335369a0. [DOI] [PubMed] [Google Scholar]
  23. Cheng K. C., Moss B. Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes. J Virol. 1987 Apr;61(4):1286–1290. doi: 10.1128/jvi.61.4.1286-1290.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Cheng K. C., Smith G. L., Moss B. Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus. J Virol. 1986 Nov;60(2):337–344. doi: 10.1128/jvi.60.2.337-344.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Child S. J., Palumbo G. J., Buller R. M., Hruby D. E. Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo. Virology. 1990 Feb;174(2):625–629. doi: 10.1016/0042-6822(90)90119-c. [DOI] [PubMed] [Google Scholar]
  26. Cochran M. A., Puckett C., Moss B. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol. 1985 Apr;54(1):30–37. doi: 10.1128/jvi.54.1.30-37.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Condit R. C., Motyczka A., Spizz G. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology. 1983 Jul 30;128(2):429–443. doi: 10.1016/0042-6822(83)90268-4. [DOI] [PubMed] [Google Scholar]
  28. Coupar B. E., Andrew M. E., Both G. W., Boyle D. B. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol. 1986 Dec;16(12):1479–1487. doi: 10.1002/eji.1830161203. [DOI] [PubMed] [Google Scholar]
  29. Coupar B. E., Andrew M. E., Boyle D. B., Blanden R. V. Immune responses to H-2Kd antigen expressed by recombinant vaccinia virus. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7879–7882. doi: 10.1073/pnas.83.20.7879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Dales S., Pogo B. G. Biology of poxviruses. Virol Monogr. 1981;18:1–109. doi: 10.1007/978-3-7091-8625-1. [DOI] [PubMed] [Google Scholar]
  31. DeLange A. M., McFadden G. Sequence-nonspecific replication of transfected plasmid DNA in poxvirus-infected cells. Proc Natl Acad Sci U S A. 1986 Feb;83(3):614–618. doi: 10.1073/pnas.83.3.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Deubel V., Kinney R. M., Esposito J. J., Cropp C. B., Vorndam A. V., Monath T. P., Trent D. W. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol. 1988 Aug;69(Pt 8):1921–1929. doi: 10.1099/0022-1317-69-8-1921. [DOI] [PubMed] [Google Scholar]
  33. Drillien R., Spehner D., Kirn A., Giraudon P., Buckland R., Wild F., Lecocq J. P. Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1252–1256. doi: 10.1073/pnas.85.4.1252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Earl P. L., Moss B., Morrison R. P., Wehrly K., Nishio J., Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science. 1986 Nov 7;234(4777):728–731. doi: 10.1126/science.3490689. [DOI] [PubMed] [Google Scholar]
  35. Elango N., Prince G. A., Murphy B. R., Venkatesan S., Chanock R. M., Moss B. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1906–1910. doi: 10.1073/pnas.83.6.1906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Elroy-Stein O., Fuerst T. R., Moss B. Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6126–6130. doi: 10.1073/pnas.86.16.6126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Esposito J. J., Knight J. C., Shaddock J. H., Novembre F. J., Baer G. M. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology. 1988 Jul;165(1):313–316. doi: 10.1016/0042-6822(88)90692-7. [DOI] [PubMed] [Google Scholar]
  38. Estin C. D., Stevenson U. S., Plowman G. D., Hu S. L., Sridhar P., Hellström I., Brown J. P., Hellström K. E. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1052–1056. doi: 10.1073/pnas.85.4.1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Falkner F. G., Chakrabarti S., Moss B. pUV I: a new vaccinia virus insertion and expression vector. Nucleic Acids Res. 1987 Sep 11;15(17):7192–7192. doi: 10.1093/nar/15.17.7192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Falkner F. G., Fuerst T. R., Moss B. Use of vaccinia virus vectors to study the synthesis, intracellular localization, and action of the human immunodeficiency virus trans-activator protein. Virology. 1988 Jun;164(2):450–457. doi: 10.1016/0042-6822(88)90559-4. [DOI] [PubMed] [Google Scholar]
  41. Falkner F. G., Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol. 1988 Jun;62(6):1849–1854. doi: 10.1128/jvi.62.6.1849-1854.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Fathi Z., Sridhar P., Pacha R. F., Condit R. C. Efficient targeted insertion of an unselected marker into the vaccinia virus genome. Virology. 1986 Nov;155(1):97–105. doi: 10.1016/0042-6822(86)90171-6. [DOI] [PubMed] [Google Scholar]
  43. Fischetti V. A., Hodges W. M., Hruby D. E. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science. 1989 Jun 23;244(4911):1487–1490. doi: 10.1126/science.2660266. [DOI] [PubMed] [Google Scholar]
  44. Fisher-Hoch S. P., McCormick J. B., Auperin D., Brown B. G., Castor M., Perez G., Ruo S., Conaty A., Brammer L., Bauer S. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A. 1989 Jan;86(1):317–321. doi: 10.1073/pnas.86.1.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Flexner C., Broyles S. S., Earl P., Chakrabarti S., Moss B. Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses. Virology. 1988 Oct;166(2):339–349. doi: 10.1016/0042-6822(88)90504-1. [DOI] [PubMed] [Google Scholar]
  46. Flexner C., Hügin A., Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature. 1987 Nov 19;330(6145):259–262. doi: 10.1038/330259a0. [DOI] [PubMed] [Google Scholar]
  47. Flexner C., Murphy B. R., Rooney J. F., Wohlenberg C., Yuferov V., Notkins A. L., Moss B. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature. 1988 Sep 15;335(6187):259–262. doi: 10.1038/335259a0. [DOI] [PubMed] [Google Scholar]
  48. Franke C. A., Berry E. S., Smith A. W., Hruby D. E. Immunisation of cattle with a recombinant togavirus-vaccinia virus strain. Res Vet Sci. 1985 Jul;39(1):113–115. [PubMed] [Google Scholar]
  49. Franke C. A., Hruby D. E. Association of non-viral proteins with recombinant vaccinia virus virions. Arch Virol. 1987;94(3-4):347–351. doi: 10.1007/BF01310729. [DOI] [PubMed] [Google Scholar]
  50. Franke C. A., Hruby D. E. Expression of recombinant vaccinia virus-derived alphavirus proteins in mosquito cells. J Gen Virol. 1985 Dec;66(Pt 12):2761–2765. doi: 10.1099/0022-1317-66-12-2761. [DOI] [PubMed] [Google Scholar]
  51. Franke C. A., Hruby D. E. Use of the gene encoding neomycin phosphotransferase II to convect linked markers into the vaccinia virus genome. Nucleic Acids Res. 1988 Feb 25;16(4):1634–1634. doi: 10.1093/nar/16.4.1634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Franke C. A., Rice C. M., Strauss J. H., Hruby D. E. Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants. Mol Cell Biol. 1985 Aug;5(8):1918–1924. doi: 10.1128/mcb.5.8.1918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Fuerst T. R., Earl P. L., Moss B. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol. 1987 Jul;7(7):2538–2544. doi: 10.1128/mcb.7.7.2538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Fuerst T. R., Fernandez M. P., Moss B. Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2549–2553. doi: 10.1073/pnas.86.8.2549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Fuerst T. R., Niles E. G., Studier F. W., Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122–8126. doi: 10.1073/pnas.83.21.8122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Gilbert J. H., Pedersen N. C., Nunberg J. H. Feline leukemia virus envelope protein expression encoded by a recombinant vaccinia virus: apparent lack of immunogenicity in vaccinated animals. Virus Res. 1987 Feb;7(1):49–67. doi: 10.1016/0168-1702(87)90057-8. [DOI] [PubMed] [Google Scholar]
  57. Gillespie J. H., Geissinger C., Scott F. W., Higgins W. P., Holmes D. F., Perkus M., Mercer S., Paoletti E. Response of dairy calves to vaccinia viruses that express foreign genes. J Clin Microbiol. 1986 Feb;23(2):283–288. doi: 10.1128/jcm.23.2.283-288.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Good M. F., Maloy W. L., Lunde M. N., Margalit H., Cornette J. L., Smith G. L., Moss B., Miller L. H., Berzofsky J. A. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science. 1987 Feb 27;235(4792):1059–1062. doi: 10.1126/science.2434994. [DOI] [PubMed] [Google Scholar]
  59. Good M. F., Miller L. H., Kumar S., Quakyi I. A., Keister D., Adams J. H., Moss B., Berzofsky J. A., Carter R. Limited immunological recognition of critical malaria vaccine candidate antigens. Science. 1988 Oct 28;242(4878):574–577. doi: 10.1126/science.2902690. [DOI] [PubMed] [Google Scholar]
  60. Graham F. L., van der Eb A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973 Apr;52(2):456–467. doi: 10.1016/0042-6822(73)90341-3. [DOI] [PubMed] [Google Scholar]
  61. Hill M. J., Melville D. M., Lennard-Jones J. E., Neale K., Ritchie J. K. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet. 1987 Jul 25;2(8552):185–186. doi: 10.1016/s0140-6736(87)90766-5. [DOI] [PubMed] [Google Scholar]
  62. Hollingshead S. K., Fischetti V. A., Scott J. R. Complete nucleotide sequence of type 6 M protein of the group A Streptococcus. Repetitive structure and membrane anchor. J Biol Chem. 1986 Feb 5;261(4):1677–1686. [PubMed] [Google Scholar]
  63. Hooda-Dhingra U., Thompson C. L., Condit R. C. Detailed phenotypic characterization of five temperature-sensitive mutants in the 22- and 147-kilodalton subunits of vaccinia virus DNA-dependent RNA polymerase. J Virol. 1989 Feb;63(2):714–729. doi: 10.1128/jvi.63.2.714-729.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Hruby D. E., Ball L. A. Control of expression of the vaccinia virus thymidine kinase gene. J Virol. 1981 Nov;40(2):456–464. doi: 10.1128/jvi.40.2.456-464.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Hruby D. E., Guarino L. A., Kates J. R. Vaccinia virus replication. I. Requirement for the host-cell nucleus. J Virol. 1979 Feb;29(2):705–715. doi: 10.1128/jvi.29.2.705-715.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Hruby D. E., Hodges W. M., Wilson E. M., Franke C. A., Fischetti V. A. Expression of streptococcal M protein in mammalian cells. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5714–5717. doi: 10.1073/pnas.85.15.5714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Hruby D. E., Lynn D. L., Condit R. C., Kates J. R. Cellular differences in the molecular mechanisms of vaccinia virus host range restriction. J Gen Virol. 1980 Apr;47(2):485–488. doi: 10.1099/0022-1317-47-2-485. [DOI] [PubMed] [Google Scholar]
  68. Hruby D. E., Lynn D. L., Kates J. R. Vaccinia virus replication requires active participation of the host cell transcriptional apparatus. Proc Natl Acad Sci U S A. 1979 Apr;76(4):1887–1890. doi: 10.1073/pnas.76.4.1887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Hruby D. E. Present and future applications of vaccinia virus as a vector. Vet Parasitol. 1988 Sep;29(2-3):281–292. doi: 10.1016/0304-4017(88)90129-x. [DOI] [PubMed] [Google Scholar]
  70. Hruby D. E., Thomas G., Herbert E., Franke C. A. Use of vaccinia virus as a neuropeptide expression vector. Methods Enzymol. 1986;124:295–309. doi: 10.1016/0076-6879(86)24022-7. [DOI] [PubMed] [Google Scholar]
  71. Hu S. L., Plowman G. D., Sridhar P., Stevenson U. S., Brown J. P., Estin C. D. Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. J Virol. 1988 Jan;62(1):176–180. doi: 10.1128/jvi.62.1.176-180.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Huang C., Samsonoff W. A., Grzelecki A. Vaccinia virus recombinants expressing an 11-kilodalton beta-galactosidase fusion protein incorporate active beta-galactosidase in virus particles. J Virol. 1988 Oct;62(10):3855–3861. doi: 10.1128/jvi.62.10.3855-3861.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Jones E. V., Moss B. Mapping of the vaccinia virus DNA polymerase gene by marker rescue and cell-free translation of selected RNA. J Virol. 1984 Jan;49(1):72–77. doi: 10.1128/jvi.49.1.72-77.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Jones E. V., Puckett C., Moss B. DNA-dependent RNA polymerase subunits encoded within the vaccinia virus genome. J Virol. 1987 Jun;61(6):1765–1771. doi: 10.1128/jvi.61.6.1765-1771.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Jones L., Ristow S., Yilma T., Moss B. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Nature. 1986 Feb 13;319(6054):543–543. doi: 10.1038/319543a0. [DOI] [PubMed] [Google Scholar]
  76. Jonjić S., del Val M., Keil G. M., Reddehase M. J., Koszinowski U. H. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol. 1988 May;62(5):1653–1658. doi: 10.1128/jvi.62.5.1653-1658.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Kakach L. T., Wasmoen T. L., Collett M. S. Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression. J Virol. 1988 Mar;62(3):826–833. doi: 10.1128/jvi.62.3.826-833.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Kieny M. P., Lathe R., Drillien R., Spehner D., Skory S., Schmitt D., Wiktor T., Koprowski H., Lecocq J. P. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature. 1984 Nov 8;312(5990):163–166. doi: 10.1038/312163a0. [DOI] [PubMed] [Google Scholar]
  79. King A. M., Stott E. J., Langer S. J., Young K. K., Ball L. A., Wertz G. W. Recombinant vaccinia viruses carrying the N gene of human respiratory syncytial virus: studies of gene expression in cell culture and immune response in mice. J Virol. 1987 Sep;61(9):2885–2890. doi: 10.1128/jvi.61.9.2885-2890.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Kinney R. M., Esposito J. J., Johnson B. J., Roehrig J. T., Mathews J. H., Barrett A. D., Trent D. W. Recombinant vaccinia/Venezuelan equine encephalitis (VEE) virus expresses VEE structural proteins. J Gen Virol. 1988 Dec;69(Pt 12):3005–3013. doi: 10.1099/0022-1317-69-12-3005. [DOI] [PubMed] [Google Scholar]
  81. Kinney R. M., Esposito J. J., Mathews J. H., Johnson B. J., Roehrig J. T., Barrett A. D., Trent D. W. Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol. 1988 Dec;62(12):4697–4702. doi: 10.1128/jvi.62.12.4697-4702.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Klavinskis L. S., Whitton J. L., Oldstone M. B. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol. 1989 Oct;63(10):4311–4316. doi: 10.1128/jvi.63.10.4311-4316.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Koenig S., Earl P., Powell D., Pantaleo G., Merli S., Moss B., Fauci A. S. Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8638–8642. doi: 10.1073/pnas.85.22.8638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. LANCEFIELD R. C. Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962 Sep;89:307–313. [PubMed] [Google Scholar]
  85. Langford C. J., Edwards S. J., Smith G. L., Mitchell G. F., Moss B., Kemp D. J., Anders R. F. Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity. Mol Cell Biol. 1986 Sep;6(9):3191–3199. doi: 10.1128/mcb.6.9.3191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Lathe R., Kieny M. P., Gerlinger P., Clertant P., Guizani I., Cuzin F., Chambon P. Tumour prevention and rejection with recombinant vaccinia. 1987 Apr 30-May 6Nature. 326(6116):878–880. doi: 10.1038/326878a0. [DOI] [PubMed] [Google Scholar]
  87. Lew A. M., Anders R. F., Edwards S. J., Langford C. J. Comparison of antibody avidity and titre elicited by peptide as a protein conjugate or as expressed in vaccinia. Immunology. 1988 Oct;65(2):311–314. [PMC free article] [PubMed] [Google Scholar]
  88. Li Y., Luo L. Z., Snyder R. M., Wagner R. R. Expression of the M gene of vesicular stomatitis virus cloned in various vaccinia virus vectors. J Virol. 1988 Mar;62(3):776–782. doi: 10.1128/jvi.62.3.776-782.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Mackett M., Arrand J. R. Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J. 1985 Dec 1;4(12):3229–3234. doi: 10.1002/j.1460-2075.1985.tb04070.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Mackett M., Smith G. L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol. 1984 Mar;49(3):857–864. doi: 10.1128/jvi.49.3.857-864.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Mackett M., Smith G. L. Vaccinia virus expression vectors. J Gen Virol. 1986 Oct;67(Pt 10):2067–2082. doi: 10.1099/0022-1317-67-10-2067. [DOI] [PubMed] [Google Scholar]
  92. Mackett M., Yilma T., Rose J. K., Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science. 1985 Jan 25;227(4685):433–435. doi: 10.1126/science.2981435. [DOI] [PubMed] [Google Scholar]
  93. Marchioli C. C., Yancey R. J., Jr, Petrovskis E. A., Timmins J. G., Post L. E. Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells. J Virol. 1987 Dec;61(12):3977–3982. doi: 10.1128/jvi.61.12.3977-3982.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Martin S., Moss B., Berman P. W., Laskey L. A., Rouse B. T. Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells. J Virol. 1987 Mar;61(3):726–734. doi: 10.1128/jvi.61.3.726-734.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Martin S., Rouse B. T. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection. J Immunol. 1987 May 15;138(10):3431–3437. [PubMed] [Google Scholar]
  96. McLaughlin-Taylor E., Willey D. E., Cantin E. M., Eberle R., Moss B., Openshaw H. A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice. J Gen Virol. 1988 Jul;69(Pt 7):1731–1734. doi: 10.1099/0022-1317-69-7-1731. [DOI] [PubMed] [Google Scholar]
  97. Michaels R. H., Norden C. W. Pharyngeal colonization with Haemophilus influenzae type b: a longitudinal study of families with a child with meningitis or epiglottitis due to H. influenzae type b. J Infect Dis. 1977 Aug;136(2):222–228. doi: 10.1093/infdis/136.2.222. [DOI] [PubMed] [Google Scholar]
  98. Miner J. N., Weinrich S. L., Hruby D. E. Molecular dissection of cis-acting regulatory elements from 5'-proximal regions of a vaccinia virus late gene cluster. J Virol. 1988 Jan;62(1):297–304. doi: 10.1128/jvi.62.1.297-304.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Mizukami T., Fuerst T. R., Berger E. A., Moss B. Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9273–9277. doi: 10.1073/pnas.85.23.9273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Mizuochi T., Hügin A. W., Morse H. C., 3rd, Singer A., Buller R. M. Role of lymphokine-secreting CD8+ T cells in cytotoxic T lymphocyte responses against vaccinia virus. J Immunol. 1989 Jan 1;142(1):270–273. [PubMed] [Google Scholar]
  101. Moss B., Flexner C. Vaccinia virus expression vectors. Annu Rev Immunol. 1987;5:305–324. doi: 10.1146/annurev.iy.05.040187.001513. [DOI] [PubMed] [Google Scholar]
  102. Moss B., Smith G. L., Gerin J. L., Purcell R. H. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature. 1984 Sep 6;311(5981):67–69. doi: 10.1038/311067a0. [DOI] [PubMed] [Google Scholar]
  103. Nakano E., Panicali D., Paoletti E. Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1593–1596. doi: 10.1073/pnas.79.5.1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Ohishi K., Maruyama T., Shida H., Nishimaki J., Miki K., Sagata N., Ikawa Y., Sugimoto M. Immunogenicity of a recombinant vaccinia virus expressing envelope a glycoprotein of bovine leukaemia virus. Vaccine. 1988 Oct;6(5):428–432. doi: 10.1016/0264-410x(88)90144-2. [DOI] [PubMed] [Google Scholar]
  105. Olmsted R. A., Elango N., Prince G. A., Murphy B. R., Johnson P. R., Moss B., Chanock R. M., Collins P. L. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7462–7466. doi: 10.1073/pnas.83.19.7462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Olmsted R. A., Murphy B. R., Lawrence L. A., Elango N., Moss B., Collins P. L. Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus. J Virol. 1989 Jan;63(1):411–420. doi: 10.1128/jvi.63.1.411-420.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Panicali D., Davis S. W., Mercer S. R., Paoletti E. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol. 1981 Mar;37(3):1000–1010. doi: 10.1128/jvi.37.3.1000-1010.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Panicali D., Grzelecki A., Huang C. Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression. Gene. 1986;47(2-3):193–199. doi: 10.1016/0378-1119(86)90063-6. [DOI] [PubMed] [Google Scholar]
  109. Paoletti E., Grady L. J. Transcriptional complexity of vaccinia virus in vivo and in vitro. J Virol. 1977 Sep;23(3):608–615. doi: 10.1128/jvi.23.3.608-615.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Paoletti E., Lipinskas B. R., Samsonoff C., Mercer S., Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A. 1984 Jan;81(1):193–197. doi: 10.1073/pnas.81.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Patel D. D., Ray C. A., Drucker R. P., Pickup D. J. A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9431–9435. doi: 10.1073/pnas.85.24.9431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Paterson R. G., Lamb R. A., Moss B., Murphy B. R. Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity. J Virol. 1987 Jun;61(6):1972–1977. doi: 10.1128/jvi.61.6.1972-1977.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Pavirani A., Meulien P., Harrer H., Dott K., Mischler F., Wiesel M. L., Mazurier C., Cazenave J. P., Lecocq J. P. Two independent domains of factor VIII co-expressed using recombinant vaccinia viruses have procoagulant activity. Biochem Biophys Res Commun. 1987 May 29;145(1):234–240. doi: 10.1016/0006-291x(87)91311-8. [DOI] [PubMed] [Google Scholar]
  114. Pensiero M. N., Jennings G. B., Schmaljohn C. S., Hay J. Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. J Virol. 1988 Mar;62(3):696–702. doi: 10.1128/jvi.62.3.696-702.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Perkus M. E., Limbach K., Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol. 1989 Sep;63(9):3829–3836. doi: 10.1128/jvi.63.9.3829-3836.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Perkus M. E., Piccini A., Lipinskas B. R., Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science. 1985 Sep 6;229(4717):981–984. doi: 10.1126/science.2992092. [DOI] [PubMed] [Google Scholar]
  117. Piccini A., Paoletti E. The use of vaccinia virus for the construction of recombinant vaccines. Bioessays. 1986 Dec;5(6):248–252. doi: 10.1002/bies.950050604. [DOI] [PubMed] [Google Scholar]
  118. Porter J. G., Wang Y., Schwartz K., Arfsten A., Loffredo A., Spratt K., Schenk D. B., Fuller F., Scarborough R. M., Lewicki J. A. Characterization of the atrial natriuretic peptide clearance receptor using a vaccinia virus expression vector. J Biol Chem. 1988 Dec 15;263(35):18827–18833. [PubMed] [Google Scholar]
  119. Ramshaw I. A., Andrew M. E., Phillips S. M., Boyle D. B., Coupar B. E. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature. 1987 Oct 8;329(6139):545–546. doi: 10.1038/329545a0. [DOI] [PubMed] [Google Scholar]
  120. Reddy V. B., Beck A. K., Garramone A. J., Vellucci V., Lustbader J., Bernstine E. G. Expression of human choriogonadotropin in monkey cells using a single simian virus 40 vector. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3644–3648. doi: 10.1073/pnas.82.11.3644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Rice C. M., Franke C. A., Strauss J. H., Hruby D. E. Expression of Sindbis virus structural proteins via recombinant vaccinia virus: synthesis, processing, and incorporation into mature Sindbis virions. J Virol. 1985 Oct;56(1):227–239. doi: 10.1128/jvi.56.1.227-239.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Robbins A., Freeman P. Obstacles to developing vaccines for the Third World. Sci Am. 1988 Nov;259(5):126–133. doi: 10.1038/scientificamerican1188-126. [DOI] [PubMed] [Google Scholar]
  123. Rodriguez D., Rodriguez J. R., Rodriguez J. F., Trauber D., Esteban M. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1287–1291. doi: 10.1073/pnas.86.4.1287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Rodriguez J. F., Esteban M. Plaque size phenotype as a selectable marker to generate vaccinia virus recombinants. J Virol. 1989 Feb;63(2):997–1001. doi: 10.1128/jvi.63.2.997-1001.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Rodriguez J. F., Rodriguez D., Rodriguez J. R., McGowan E. B., Esteban M. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1667–1671. doi: 10.1073/pnas.85.5.1667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Rooney J. F., Wohlenberg C., Cremer K. J., Moss B., Notkins A. L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol. 1988 May;62(5):1530–1534. doi: 10.1128/jvi.62.5.1530-1534.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Rupprecht C. E., Wiktor T. J., Johnston D. H., Hamir A. N., Dietzschold B., Wunner W. H., Glickman L. T., Koprowski H. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7947–7950. doi: 10.1073/pnas.83.20.7947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Shepard B., Panicali D., Huang C. Transient expression system to measure the efficiency of vaccinia promoter regions. Plasmid. 1987 Jul;18(1):16–23. doi: 10.1016/0147-619x(87)90074-6. [DOI] [PubMed] [Google Scholar]
  129. Shida H., Hinuma Y., Hatanaka M., Morita M., Kidokoro M., Suzuki K., Maruyama T., Takahashi-Nishimaki F., Sugimoto M., Kitamura R. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J Virol. 1988 Dec;62(12):4474–4480. doi: 10.1128/jvi.62.12.4474-4480.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Shida H., Tochikura T., Sato T., Konno T., Hirayoshi K., Seki M., Ito Y., Hatanaka M., Hinuma Y., Sugimoto M. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J. 1987 Nov;6(11):3379–3384. doi: 10.1002/j.1460-2075.1987.tb02660.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Slabaugh M., Roseman N., Davis R., Mathews C. Vaccinia virus-encoded ribonucleotide reductase: sequence conservation of the gene for the small subunit and its amplification in hydroxyurea-resistant mutants. J Virol. 1988 Feb;62(2):519–527. doi: 10.1128/jvi.62.2.519-527.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Smith G. L., Godson G. N., Nussenzweig V., Nussenzweig R. S., Barnwell J., Moss B. Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus. Science. 1984 Apr 27;224(4647):397–399. doi: 10.1126/science.6200932. [DOI] [PubMed] [Google Scholar]
  133. Smith G. L., Levin J. Z., Palese P., Moss B. Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology. 1987 Oct;160(2):336–345. doi: 10.1016/0042-6822(87)90004-3. [DOI] [PubMed] [Google Scholar]
  134. Smith G. L., Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene. 1983 Nov;25(1):21–28. doi: 10.1016/0378-1119(83)90163-4. [DOI] [PubMed] [Google Scholar]
  135. Smith G. L., Murphy B. R., Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A. 1983 Dec;80(23):7155–7159. doi: 10.1073/pnas.80.23.7155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Spriggs M. K., Collins P. L., Tierney E., London W. T., Murphy B. R. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection. J Virol. 1988 Apr;62(4):1293–1296. doi: 10.1128/jvi.62.4.1293-1296.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Spriggs M. K., Murphy B. R., Prince G. A., Olmsted R. A., Collins P. L. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol. 1987 Nov;61(11):3416–3423. doi: 10.1128/jvi.61.11.3416-3423.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Stamatos N. M., Chakrabarti S., Moss B., Hare J. D. Expression of polyomavirus virion proteins by a vaccinia virus vector: association of VP1 and VP2 with the nuclear framework. J Virol. 1987 Feb;61(2):516–525. doi: 10.1128/jvi.61.2.516-525.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Stoflet E. S., Koeberl D. D., Sarkar G., Sommer S. S. Genomic amplification with transcript sequencing. Science. 1988 Jan 29;239(4839):491–494. doi: 10.1126/science.3340835. [DOI] [PubMed] [Google Scholar]
  140. Stott E. J., Ball L. A., Young K. K., Furze J., Wertz G. W. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol. 1986 Nov;60(2):607–613. doi: 10.1128/jvi.60.2.607-613.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Stott E. J., Taylor G., Ball L. A., Anderson K., Young K. K., King A. M., Wertz G. W. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol. 1987 Dec;61(12):3855–3861. doi: 10.1128/jvi.61.12.3855-3861.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Stunnenberg H. G., Lange H., Philipson L., van Miltenburg R. T., van der Vliet P. C. High expression of functional adenovirus DNA polymerase and precursor terminal protein using recombinant vaccinia virus. Nucleic Acids Res. 1988 Mar 25;16(6):2431–2444. doi: 10.1093/nar/16.6.2431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Sullivan V., Smith G. L. Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) by recombinant vaccinia virus: neutralization of HSV-1 infectivity with anti-gG antibody. J Gen Virol. 1987 Oct;68(Pt 10):2587–2598. doi: 10.1099/0022-1317-68-10-2587. [DOI] [PubMed] [Google Scholar]
  144. Takahashi-Nishimaki F., Suzuki K., Morita M., Maruyama T., Miki K., Hashizume S., Sugimoto M. Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination. J Gen Virol. 1987 Oct;68(Pt 10):2705–2710. doi: 10.1099/0022-1317-68-10-2705. [DOI] [PubMed] [Google Scholar]
  145. Takahashi H., Cohen J., Hosmalin A., Cease K. B., Houghten R., Cornette J. L., DeLisi C., Moss B., Germain R. N., Berzofsky J. A. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1988 May;85(9):3105–3109. doi: 10.1073/pnas.85.9.3105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Tamin A., Villarreal E. C., Weinrich S. L., Hruby D. E. Nucleotide sequence and molecular genetic analysis of the vaccinia virus HindIII N/M region encoding the genes responsible for resistance to alpha-amanitin. Virology. 1988 Jul;165(1):141–150. doi: 10.1016/0042-6822(88)90667-8. [DOI] [PubMed] [Google Scholar]
  147. Taylor J., Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine. 1988 Dec;6(6):466–468. doi: 10.1016/0264-410x(88)90091-6. [DOI] [PubMed] [Google Scholar]
  148. Taylor J., Weinberg R., Kawaoka Y., Webster R. G., Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine. 1988 Dec;6(6):504–508. doi: 10.1016/0264-410x(88)90101-6. [DOI] [PubMed] [Google Scholar]
  149. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine. 1988 Dec;6(6):497–503. doi: 10.1016/0264-410x(88)90100-4. [DOI] [PubMed] [Google Scholar]
  150. Tengelsen L. A., Slabaugh M. B., Bibler J. K., Hruby D. E. Nucleotide sequence and molecular genetic analysis of the large subunit of ribonucleotide reductase encoded by vaccinia virus. Virology. 1988 May;164(1):121–131. doi: 10.1016/0042-6822(88)90627-7. [DOI] [PubMed] [Google Scholar]
  151. Thomas G., Herbert E., Hruby D. E. Expression and cell type--specific processing of human preproenkephalin with a vaccinia recombinant. Science. 1986 Jun 27;232(4758):1641–1643. doi: 10.1126/science.3754979. [DOI] [PubMed] [Google Scholar]
  152. Thomas G., Thorne B. A., Hruby D. E. Gene transfer techniques to study neuropeptide processing. Annu Rev Physiol. 1988;50:323–332. doi: 10.1146/annurev.ph.50.030188.001543. [DOI] [PubMed] [Google Scholar]
  153. Thomas G., Thorne B. A., Thomas L., Allen R. G., Hruby D. E., Fuller R., Thorner J. Yeast KEX2 endopeptidase correctly cleaves a neuroendocrine prohormone in mammalian cells. Science. 1988 Jul 8;241(4862):226–230. doi: 10.1126/science.3291117. [DOI] [PubMed] [Google Scholar]
  154. Thomas P. S. Hybridization of denatured RNA transferred or dotted nitrocellulose paper. Methods Enzymol. 1983;100:255–266. doi: 10.1016/0076-6879(83)00060-9. [DOI] [PubMed] [Google Scholar]
  155. Tolson N. D., Charlton K. M., Casey G. A., Knowles M. K., Rupprecht C. E., Lawson K. F., Campbell J. B. Immunization of foxes against rabies with a vaccinia recombinant virus expressing the rabies glycoprotein. Arch Virol. 1988;102(3-4):297–301. doi: 10.1007/BF01310835. [DOI] [PubMed] [Google Scholar]
  156. Tomley F. M., Mockett A. P., Boursnell M. E., Binns M. M., Cook J. K., Brown T. D., Smith G. L. Expression of the infectious bronchitis virus spike protein by recombinant vaccinia virus and induction of neutralizing antibodies in vaccinated mice. J Gen Virol. 1987 Sep;68(Pt 9):2291–2298. doi: 10.1099/0022-1317-68-9-2291. [DOI] [PubMed] [Google Scholar]
  157. Tsao H., Liu G. Q., Ruan L., Chu C. M. Construction and application of plasmids containing bidirectional promoters of vaccinia virus. J Virol. 1988 Dec;62(12):4832–4834. doi: 10.1128/jvi.62.12.4832-4834.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Venkatesan S., Baroudy B. M., Moss B. Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene. Cell. 1981 Sep;25(3):805–813. doi: 10.1016/0092-8674(81)90188-4. [DOI] [PubMed] [Google Scholar]
  159. Vijaya S., Elango N., Zavala F., Moss B. Transport to the cell surface of a peptide sequence attached to the truncated C terminus of an N-terminally anchored integral membrane protein. Mol Cell Biol. 1988 Apr;8(4):1709–1714. doi: 10.1128/mcb.8.4.1709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Villarreal L. P., Berg P. Hybridization in situ of SV40 plaques: detection of recombinant SV40 virus carrying specific sequences of nonviral DNA. Science. 1977 Apr 8;196(4286):183–185. doi: 10.1126/science.191907. [DOI] [PubMed] [Google Scholar]
  161. Wakamiya N., Wang Y. L., Imai H., Gu H. X., Ueda S., Kato S. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity. Cancer Immunol Immunother. 1986;23(2):125–129. doi: 10.1007/BF00199818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Walker B. D., Flexner C., Paradis T. J., Fuller T. C., Hirsch M. S., Schooley R. T., Moss B. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science. 1988 Apr 1;240(4848):64–66. doi: 10.1126/science.2451288. [DOI] [PubMed] [Google Scholar]
  163. Weinrich S. L., Hruby D. E. A tandemly-oriented late gene cluster within the vaccinia virus genome. Nucleic Acids Res. 1986 Apr 11;14(7):3003–3016. doi: 10.1093/nar/14.7.3003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Wertz G. W., Stott E. J., Young K. K., Anderson K., Ball L. A. Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol. 1987 Feb;61(2):293–301. doi: 10.1128/jvi.61.2.293-301.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Willey R. L., Smith D. H., Lasky L. A., Theodore T. S., Earl P. L., Moss B., Capon D. J., Martin M. A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol. 1988 Jan;62(1):139–147. doi: 10.1128/jvi.62.1.139-147.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  166. Wilson E. M., Hodges W. M., Hruby D. E. Construction of recombinant vaccinia virus strains using single-stranded DNA insertion vectors. Gene. 1986;49(2):207–213. doi: 10.1016/0378-1119(86)90281-7. [DOI] [PubMed] [Google Scholar]
  167. Wright C. F., Moss B. Identification of factors specific for transcription of the late class of vaccinia virus genes. J Virol. 1989 Oct;63(10):4224–4233. doi: 10.1128/jvi.63.10.4224-4233.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Wright C. F., Moss B. In vitro synthesis of vaccinia virus late mRNA containing a 5' poly(A) leader sequence. Proc Natl Acad Sci U S A. 1987 Dec;84(24):8883–8887. doi: 10.1073/pnas.84.24.8883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. Yilma T., Ristow S. S., Moss B., Jones L. A novel approach for the production of monoclonal antibodies using infectious vaccinia virus recombinants. Hybridoma. 1987 Aug;6(4):329–335. doi: 10.1089/hyb.1987.6.329. [DOI] [PubMed] [Google Scholar]
  170. Zarling J. M., Morton W., Moran P. A., McClure J., Kosowski S. G., Hu S. L. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. 1986 Sep 25-Oct 1Nature. 323(6086):344–346. doi: 10.1038/323344a0. [DOI] [PubMed] [Google Scholar]
  171. Zhao B. T., Prince G., Horswood R., Eckels K., Summers P., Chanock R., Lai C. J. Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus. J Virol. 1987 Dec;61(12):4019–4022. doi: 10.1128/jvi.61.12.4019-4022.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Zoller M. J., Smith M. Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. Nucleic Acids Res. 1982 Oct 25;10(20):6487–6500. doi: 10.1093/nar/10.20.6487. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES